Hospital
Mymichigan Medical Center West Branch
Mymichigan Medical Center West Branch was paid $10.33M by Medicaid between Jan 2018 and Dec 2024, across 207 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoMYMICHIGAN MEDICAL CENTER WEST BRANCH
WEST BRANCH, MI 48661
WEST BRANCH, MI 48661
33aNPI1538566765assigned 12/03/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.33M
24GClaims347,737
24DCodes billed207
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#62 of 86
Median peer was paid$21.55M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JAMES, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,365 | $1.28M | |
| 2019 | 41,956 | $1.22M | |
| 2020 | 39,994 | $1.10M | |
| 2021 | 53,919 | $1.57M | |
| 2022 | 61,614 | $1.81M | |
| 2023 | 62,386 | $1.82M | |
| 2024incomplete | 51,503 | $1.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 11,024 | 10,310 | $1.99M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 6,157 | 5,733 | $1.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 10,481 | 10,035 | $1.17M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.2% | 7,889 | 7,289 | $739K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 3,718 | 3,577 | $484K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.3% | 9,093 | 8,033 | $443K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 3,558 | 3,014 | $285K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 4,148 | 4,048 | $277K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 3,168 | 3,041 | $272K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 7,082 | 6,233 | $199K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 5,845 | 5,012 | $192K |
| 80061 | Lipid panel | 1.6% | 2,824 | 2,795 | $163K |
195 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,565 | $154K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 4,154 | $144K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 1,414 | $141K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 969 | $138K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 3,944 | $136K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 5,393 | $121K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 536 | $97K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 853 | $90K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 912 | $83K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,707 | $82K |
| 64493 | <1% | 126 | $80K | |
| 59025 | Fetal non-stress test | <1% | 784 | $78K |
| 97597 | <1% | 986 | $76K | |
| G0378 | Hospital observation service, per hour | <1% | 1,268 | $73K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 955 | $53K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,136 | $45K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,969 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,121 | $34K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 75 | $33K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 364 | $32K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 536 | $29K |
| 94060 | <1% | 222 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 476 | $27K |
| 64635 | <1% | 27 | $26K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 559 | $22K |
| 86900 | <1% | 1,951 | $21K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,221 | $21K |
| 80053 | Comprehensive metabolic panel | <1% | 21,042 | $18K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,492 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,151 | $15K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 40 | $14K |
| 72141 | <1% | 91 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,843 | $13K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,498 | $12K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 28 | $12K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 66 | $12K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 890 | $11K |
| 71271 | <1% | 195 | $11K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 465 | $9K |
| 76801 | <1% | 154 | $9K | |
| 45384 | <1% | 31 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 876 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,744 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,162 | $7K |
| 93971 | <1% | 127 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,066 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $6K |
| 73564 | <1% | 422 | $5K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 828 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 656 | $5K |
| 93970 | <1% | 55 | $5K | |
| 72131 | <1% | 105 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 89 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,719 | $5K |
| 93017 | <1% | 256 | $5K | |
| 73630 | <1% | 732 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,686 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 834 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 839 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 212 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 357 | $4K |
| 72110 | <1% | 129 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $3K |
| 73030 | <1% | 497 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 216 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,473 | $2K |
| 84439 | <1% | 953 | $2K | |
| 84702 | <1% | 660 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,583 | $2K |
| 86803 | <1% | 572 | $2K | |
| 83880 | <1% | 1,706 | $2K | |
| 73610 | <1% | 367 | $2K | |
| 73130 | <1% | 427 | $2K | |
| 70496 | <1% | 37 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,198 | $1K |
| 87070 | <1% | 1,398 | $1K | |
| 86140 | <1% | 3,694 | $1K | |
| 71250 | <1% | 24 | $1K | |
| 81025 | <1% | 4,956 | $1K | |
| 76536 | <1% | 31 | $1K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 30 | $1K |
| 81001 | <1% | 12,545 | $1K | |
| 97162 | <1% | 26 | $1K | |
| 72100 | <1% | 70 | $1K | |
| 83735 | <1% | 5,019 | $1K | |
| 87081 | <1% | 389 | $896.77 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,400 | $877.78 |
| 85610 | <1% | 4,037 | $861.00 | |
| 87634 | <1% | 887 | $855.98 | |
| 80306 | <1% | 1,286 | $786.67 | |
| 94726 | <1% | 165 | $748.43 | |
| 87808 | <1% | 168 | $671.04 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $650.50 |
| 73110 | <1% | 88 | $617.12 | |
| 76642 | <1% | 12 | $533.28 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,886 | $449.45 |
| 85027 | <1% | 437 | $447.68 | |
| 82728 | <1% | 190 | $443.60 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 13 | $395.08 |
| 85652 | <1% | 1,350 | $374.36 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 27 | $373.80 |
| 85730 | <1% | 2,003 | $364.78 | |
| 87186 | <1% | 588 | $364.14 | |
| 80076 | <1% | 1,191 | $363.51 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,339 | $362.94 |
| 86592 | <1% | 204 | $351.27 | |
| 82607 | <1% | 105 | $338.32 | |
| 96367 | <1% | 22 | $325.82 | |
| 74018 | <1% | 38 | $320.09 | |
| 83690 | <1% | 5,148 | $287.63 | |
| 87077 | <1% | 399 | $264.58 | |
| 87340 | <1% | 242 | $251.16 | |
| 83540 | <1% | 174 | $245.36 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 24 | $242.32 |
| 83550 | <1% | 120 | $211.32 | |
| 87276 | <1% | 1,148 | $183.54 | |
| 85379 | <1% | 1,742 | $167.94 | |
| 82570 | <1% | 115 | $152.09 | |
| 87275 | <1% | 1,148 | $142.88 | |
| 87088 | <1% | 203 | $131.33 | |
| 85651 | <1% | 200 | $129.56 | |
| 86850 | <1% | 1,744 | $128.82 | |
| 97802 | <1% | 13 | $125.00 | |
| 84145 | <1% | 985 | $121.73 | |
| 87653 | <1% | 12 | $115.14 | |
| 82962 | <1% | 3,421 | $109.28 | |
| 82951 | <1% | 20 | $107.70 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,806 | $100.99 |
| 70498 | <1% | 38 | $100.63 | |
| 84703 | <1% | 1,125 | $98.57 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 140 | $88.22 |
| 84484 | <1% | 5,679 | $87.84 | |
| 86901 | <1% | 1,950 | $77.28 | |
| 83605 | <1% | 5,132 | $76.59 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,301 | $74.44 |
| 94729 | <1% | 254 | $64.76 | |
| 81002 | <1% | 64 | $60.13 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 67 | $59.64 |
| 84100 | <1% | 139 | $51.40 | |
| 82150 | <1% | 196 | $48.84 | |
| 87040 | <1% | 1,559 | $47.74 | |
| 82565 | <1% | 54 | $43.37 | |
| 88342 | <1% | 15 | $25.16 | |
| 87075 | <1% | 80 | $16.19 | |
| 82950 | <1% | 12 | $13.25 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 200 | $11.79 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,473 | $6.86 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,549 | $3.88 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,090 | $3.70 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,608 | $2.26 |
| 84520 | <1% | 12 | $2.23 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 25 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 23 | $0.01 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,669 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 486 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,041 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 838 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 181 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 347 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 249 | $0.00 |
| 90715 | 0% | 300 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 57 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 80 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 331 | $0.00 |
| 64636 | 0% | 27 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 107 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 90 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 26 | $0.00 |
| 82800 | 0% | 13 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 27 | $0.00 |
| 64495 | 0% | 17 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 805 | $0.00 |
| A9270 | Non-covered item or service | 0% | 608 | $0.00 |
| J1741 | Injection, ibuprofen, 100 mg | 0% | 42 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,193 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 184 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 327 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,023 | $0.00 |
| 96376 | 0% | 2,166 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 612 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 201 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,759 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 232 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 83 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 269 | $0.00 |
| 64494 | 0% | 125 | $0.00 | |
| 82803 | 0% | 77 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 19 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 43 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 43 | $0.00 |
| 94750 | 0% | 48 | $0.00 | |
| 88304 | 0% | 12 | $0.00 | |
| 82810 | 0% | 15 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 42 | $0.00 |
| 96368 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMES, SARAH (MANAGER, PROVIDER ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.